Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have received an average rating of “Reduce” from the ten research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company.

A number of research analysts have issued reports on BAYRY shares. The Goldman Sachs Group assumed coverage on shares of Bayer Aktiengesellschaft in a research report on Thursday, May 30th. They set a “neutral” rating on the stock. Bank of America raised shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th.

Bayer Aktiengesellschaft Stock Up 0.7 %

Shares of Bayer Aktiengesellschaft stock opened at $7.51 on Wednesday. The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04. Bayer Aktiengesellschaft has a one year low of $6.82 and a one year high of $13.29. The business’s 50 day simple moving average is $7.46 and its two-hundred day simple moving average is $7.42.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, August 6th. The company reported $0.25 EPS for the quarter, hitting the consensus estimate of $0.25. The company had revenue of $12 billion for the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. Analysts anticipate that Bayer Aktiengesellschaft will post 1.38 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.